We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patent watch.
- Abstract
The article presents the lawsuit filed by Isis Pharmaceuticals Inc., filed a lawsuit to its rival Santaris Pharma A/S, which allegedly accusing the Santaris of illegal selling of the antisense technology that is part of the Isis's patents. It mentions that both companies develop an antisense gene silencing technology such as locked nucleic acids (LNAs) and gapped or gapmer oligonucleotides. The article also discusses the mammalian target of rapamycin (mTOR) inhibitors.
- Subjects
IONIS Pharmaceuticals Inc.; ROCHE Innovation Center Copenhagen A/S; GENE silencing; NUCLEIC acids; OLIGONUCLEOTIDES; PATENT medicines
- Publication
Nature Reviews Drug Discovery, 2011, Vol 10, Issue 11, p804
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd3583